Immunology Flashcards
(131 cards)
What deficiency is found in Hereditary Angioneurotic Oedema (HAO)?
C1 esterase inhibitor deficiency
What is the effect of C1 esterase deficiency?Which complement is found to be low?
Persistent activation of the classical complement pathway and low C4 levels due to consumption.
If Hereditary Angioneurotic Oedema (HAO) is refractory to treatment and the C4 levels stay low, what complication may develop?
SLE
For the following drug prefixes that occur just before mab (monoclonal antibody) comment on the type of monoclonal Ab:
- o
- xi
- zu
- u
- o = mouse
- xi = chimeric
- zu = humanized
- u = fully human
What are the 4 types of hypersensitivity reactions and give the mechanism and an example of each.
Clue: ACID
ACID:
Type 1 - Allergic
Mechanism: IgE-mediated (quick)
Example: Penicillin drug allergy, Bee stings
Type 2 - Cytotoxic
Mechanism: Cytotoxic/IgG-mediated
Examples: Goodpasture’s syndrome, AIHA
Type 3 - Immune complex mediated
Immune complex deposition and IgG/IgM mediated
Examples: SLE, polyarteritis nodosa, serum sickness
Type 4 - Delayed or cell-mediated
Mechanism: cell-mediated (T-helper cells activate macrophages and cytotoxic T-cells)
Example: contact dermatitis (latex)
NB: grossly simplified!
That is Job’s syndrome?
AKA: AD-HIES - autosomal dominant hyperimmunoglobulin IgE syndrome associated with high IgE level.
Characterised by the triad (SEE):
Skin and pulmonary infections
Eczema
Eosinophilia
Mnemonic: SEE if I can GEt him a JOB?
–> SEE-IGE-JOB
In a patient with severe allergic rhinitis and severe asthma, which of the following is TRUE (may be more than one answer):
A. Desensitisation will improve allergic rhinitis but not asthma
B. Desensitisation carries higher risk of morbidity in this patient.
C. Inhaled nasal corticosteroids are indicated
D. Omalizumab may be of benefit for both allergic conditions
E. Serum tests for specific IgE will show results similar to skin testing.
A. Desensitisation will improve allergic rhinitis but not asthma - FALSE (both would benefit)
B. Desensitisation carries higher risk of morbidity in this patient - TRUE
C. Inhaled nasal corticosteroids are indicated - TRUE
D. Omalizumab may be of benefit for both allergic conditions - TRUE
E. Serum tests for specific IgE will show results similar to skin testing - TRUE
What is the MOA Omalizumab?
What is the indications?
MOA:
- Recombinant humanised antibody of IgG1 subclass targeted at IgE.
- Binds free IgE in serum
- Decreases expression of high-affinity receptors upon mast cells/basophils/eosinophils
- Decreased inflammatory mediator release
Indications:
- mod-severe asthma
- Refractory idiopathic chronic urtcaria
How do Quantiferon Gold assays work?
- They are Interferon-gamma release assays (IGRA)
- Mycobacterium TB peptides stimulate the release of IFN-gamma via Th1 cells (T helper cells)
Which of the following T helper cells are implicated in the Quantiferon Gold assay (Th1, Th2 or Th17)?
Th1
Which cell type is the major antigen-presenting cell (APC) responsible for initiating immune response?
Dendritic cells
Dendritic cells (DC) present processed antigen to T-cells (TC) via the MHC complex to T-cell receptors.
Name 2 co-stimulatory pathways that ACTIVATE the T-cell.
- [DC] CD80/CD86 : CD28 [TC]
2. [DC] CD40 : CD40L [TC]
Dendritic cells (DC) present processed antigen to T-cells (TC) via the MHC complex to T-cell receptors.
Name 3 co-stimulatory pathways that INHIBIT the T-cell.
- [DC] CD80/CD86 : CTLA4 [TC]
- [DC] PD-L1/PD2-L2 : PD1 [TC]
- [DC] OX40L : OX40 [TC]
Dendritic cells present processed antigen to T-cells via the MHC complex to T-cell receptors (TCR).
Name a co-stimulatory pathways that either activates or inhibits depending upon CD28-signalling of the T-cell
[DC] ICOSL : ICOS [TC]
Activates with CD28 signalling.
With the activation of the co-stimulatory pathway of ICOSL (dendritic cells) and ICOS (T-cells), which 2 interleukins are released?
IL-3 and IL-10
Which 2 places do plasma dendritic cells migrate to to maximise interaction with circulating B-cells and T-cells?
LNs and spleen.
What is Sifalimumab?
Which condition may it be beneficial in?
Anti-IFN-alpha mAb that may be used in the treatment of adult SLE
What type of pathogens cause interferons release?
Viruses.
Describe type I and type II interferons in terms of:
- Receptor type
- Categories of interferons
- Prototypic cell(s) of origin
Type I interferons (type I receptors):
IFN-alpha - leukocyte (most cells)
IFN-beta - fibroblast (most cells)
IFN-omega - leukocyte
Type II interferons (type II receptors):
IFN-gamma - T-cells and NK-cells (lymphocytes)
What triggers the release of the following IFNs:
- IFN-alpha and IFN-beta
- IFN-gamma
- IFN-alpha and IFN-beta: viral dsRNA
2. IFN-gamma: mitogens
What are effects of type I interferons?
Interferes with viral replication:
- Induces resistance to viral replication in all cells
- Increases MHC-I expression and Ag-presentation on all cells.
- Activates dendritic cells (DC) and macrophages (Mp)
- Activates NK-cells
Which 3 cells lines are activated by interferons?
- Dendritic cells
- Macrophages
- NK-cells
How are plasmacytoid dentritic cells (pDC) distinct from conventional dendritic cells (cDC)?
- pDC respond to viral infections by secreting a lot of type I IFNs (i.e. IFN-alpha and IFN-beta)
- pDC (unlike cDC) are LESS involved in Ag-processing, , co-stimulatory molecules and MHC-II expression
What is the function of follicular helper T-cells (Tfh)?
Which co-stimulatory signals do they use?
Tfh migrate to lymphoid follicles and help B-cells class-switch and affinity maturation.
They use the following 2 co-stimulatory signals:
- [Tfh] ICOS : ICOSL [B-cell]
- [Tfh] CD40L : CD40 [B-cell]